Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis

Figure 1

Patient flow for the training cohort (a) and validation cohort (b). Chemotherapy included mFOLFOX6 and FOLFIRI.

(a)

(b)